The CRO Industry is at an inflection point as COVID-19 has changed clinical trials forever with Technology-enabled services being in the forefront as the new normal. We are witnessing the beginning of a restructuring of the clinical trial landscape. Returning to the traditional models will not be possible, even in the post-COVID world. Our broad future plans include focus on technology enablement. This is achieved by integrating disparate systems usually used in clinical trial systems and which supports us in providing the real-time insights and also data-driven decisions, which are made for the studies. Through this we are fully driven in terms of executing the next-gen clinical trials. We also plan to make a shift in our approach towards clinical development. Key lessons learnt during the pandemic and the way we have executed the six COVID-19 studies have made us more adaptable and flexible in terms of study management. We will be future proofing with real time insights - driven optimization to inform sponsor team and executive management with real time status decisions and deliver quality outcomes. There will be greater Implementation of patient engagement tools and remote monitoring.
Srinivasan H R Vice Chairman & Managing Director, TAKE Solutions
